Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lyra Therapeutics (LYRA)
NASDAQ:LYRA
Holding LYRA?
Track your performance easily
LYRA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.25 - $6.79
Previous Close$0.28
Volume812.22K
Average Volume (3M)1.23M
Market Cap
$18.39M
Enterprise Value-$12.36M
Total Cash (Recent Filing)$67.50M
Total Debt (Recent Filing)$36.75M
Price to Earnings (P/E)―
Beta0.45
Next Earnings
Nov 05, 2024EPS Estimate
-$0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.63
Shares Outstanding65,456,735
10 Day Avg. Volume646,403
30 Day Avg. Volume1,229,025
Standard Deviation0.25
R-Squared0.00
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.60
Price to Sales (P/S)9.84
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-6.79
Enterprise Value/Gross Profit-7.94
Enterprise Value/Ebitda0.14
Forecast
1Y Price Target
$2.00Price Target Upside609.22% Upside
Rating ConsensusHold
Number of Analyst Covering2
Lyra Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsThe 52-week extension results for the ENLIGHTEN-1 trial are expected to include data from a repeat treatment group, which might show a different therapeutic profile compared to the 24 weeks single implant data.
Regulatory EngagementLYRA remains confident in the non-polyp opportunity and aims to engage with the FDA in the future.
Subgroup AnalysisSubgroup analysis with nasal polyps has shown a positive effect versus sham in 3CS and nasal congestion scores, highlighting potential areas for successful treatment outcomes.
Bears Say
Clinical TrialsThe LYR-210 Phase 3 ENLIGHTEN-1 trial in surgically naïve CRS patients demonstrated failure to reach the primary endpoint for 3 cardinal symptoms (3CS) score, the Sino-Nasal Outcome Test (SNOT-22) score, and ethmoid sinus opacification with CT scans.
Regulatory ChallengesThe regulatory path ahead is seen as unclear given the miss on one of two pivotal Phase 3 studies for LYR-210.
Trial ExecutionENLIGHTEN I trial failed due to potentially less severe non-polyp CRS patients enrolling in the US.
---
Ownership Overview
28.77% Insiders
3.09% Mutual Funds
35.13% Other Institutional Investors
33.01% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
LYRA FAQ
What was Lyra Therapeutics’s price range in the past 12 months?
Lyra Therapeutics lowest stock price was $0.25 and its highest was $6.79 in the past 12 months.
What is Lyra Therapeutics’s market cap?
Currently, no data Available
When is Lyra Therapeutics’s upcoming earnings report date?
Lyra Therapeutics’s upcoming earnings report date is Nov 05, 2024 which is in 45 days.
How were Lyra Therapeutics’s earnings last quarter?
Lyra Therapeutics released its earnings results on Aug 14, 2024. The company reported -$0.74 earnings per share for the quarter, missing the consensus estimate of -$0.334 by -$0.406.
Is Lyra Therapeutics overvalued?
According to Wall Street analysts Lyra Therapeutics’s price is currently Undervalued.
Does Lyra Therapeutics pay dividends?
Lyra Therapeutics does not currently pay dividends.
What is Lyra Therapeutics’s EPS estimate?
Lyra Therapeutics’s EPS estimate is -$0.22.
How many shares outstanding does Lyra Therapeutics have?
Lyra Therapeutics has 65,456,730 shares outstanding.
What happened to Lyra Therapeutics’s price movement after its last earnings report?
Lyra Therapeutics reported an EPS of -$0.74 in its last earnings report, missing expectations of -$0.334. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Lyra Therapeutics?
Among the largest hedge funds holding Lyra Therapeutics’s share is Perceptive Advisors LLC. It holds Lyra Therapeutics’s shares valued at 4M.
---
Lyra Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.00 (609.22% Upside)
$2.00 (609.22% Upside)
Blogger Sentiment
Bullish
LYRA Sentiment 80%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 676.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.8%
Last 30 Days ▼ 12.5%
Last 30 Days ▼ 12.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-94.14%
12-Months-Change
Fundamentals
Return on Equity
-156.52%
Trailing 12-Months
Asset Growth
-24.74%
Trailing 12-Months
Company Description
Lyra Therapeutics
Lyra Therapeutics Inc a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases. The company's technology platform, XTreo, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration.
---
LYRA Stock 12 Month Forecast
Average Price Target
$2.00
▲(609.22% Upside)
Technical Analysis
---